Found: 82
Select item for more details and to access through your institution.
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
- Published in:
- Oncologist, 2024, v. 29, n. 7, p. 589, doi. 10.1093/oncolo/oyae037
- By:
- Publication type:
- Article
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
- Published in:
- Oncologist, 2024, v. 29, n. 5, p. 392, doi. 10.1093/oncolo/oyad302
- By:
- Publication type:
- Article
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 11, p. 1009, doi. 10.1093/oncolo/oyad173
- By:
- Publication type:
- Article
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 15, p. 3806, doi. 10.3390/cancers15153806
- By:
- Publication type:
- Article
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
- Published in:
- Oncologist, 2023, v. 28, n. 8, p. 714, doi. 10.1093/oncolo/oyad039
- By:
- Publication type:
- Article
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 5, p. 1, doi. 10.1002/ctm2.1267
- By:
- Publication type:
- Article
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 433, doi. 10.1093/oncolo/oyac262
- By:
- Publication type:
- Article
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00369-w
- By:
- Publication type:
- Article
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
- Published in:
- BJU International, 2022, v. 129, n. 5, p. 610, doi. 10.1111/bju.15541
- By:
- Publication type:
- Article
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29539-3
- By:
- Publication type:
- Article
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
- Published in:
- Acta Oncologica, 2022, v. 61, n. 1, p. 52, doi. 10.1080/0284186X.2021.1995041
- By:
- Publication type:
- Article
Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 189, doi. 10.3233/KCA-210127
- By:
- Publication type:
- Article
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26415-4
- By:
- Publication type:
- Article
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08630-w
- By:
- Publication type:
- Article
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08630-w
- By:
- Publication type:
- Article
Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4341, doi. 10.3390/cancers13174341
- By:
- Publication type:
- Article
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 9, p. e2122998, doi. 10.1001/jamanetworkopen.2021.22998
- By:
- Publication type:
- Article
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 2, p. 387, doi. 10.1002/ijc.33560
- By:
- Publication type:
- Article
Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 2, p. 403, doi. 10.1002/ijc.33556
- By:
- Publication type:
- Article
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies.
- Published in:
- Oncologist, 2021, v. 26, n. 6, p. 476, doi. 10.1002/onco.13770
- By:
- Publication type:
- Article
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2170, doi. 10.3390/cancers13092170
- By:
- Publication type:
- Article
Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 695, doi. 10.3390/cancers13040695
- By:
- Publication type:
- Article
Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.
- Published in:
- BJU International, 2020, v. 126, n. 6, p. 745, doi. 10.1111/bju.15160
- By:
- Publication type:
- Article
Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2927, doi. 10.3390/cancers12102927
- By:
- Publication type:
- Article
Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
- Published in:
- Abdominal Radiology, 2020, v. 45, n. 6, p. 1872, doi. 10.1007/s00261-019-02354-z
- By:
- Publication type:
- Article
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-15959-6
- By:
- Publication type:
- Article
Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. 252, doi. 10.1634/theoncologist.2019-0372
- By:
- Publication type:
- Article
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-57534-5
- By:
- Publication type:
- Article
Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.
- Published in:
- Carcinogenesis, 2018, v. 39, n. 6, p. 752, doi. 10.1093/carcin/bgy021
- By:
- Publication type:
- Article
Second‐Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
- Published in:
- Oncologist, 2018, v. 23, n. 5, p. 540, doi. 10.1634/theoncologist.2017-0534
- By:
- Publication type:
- Article
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
- Published in:
- BJU International, 2017, v. 120, n. 6, p. 782, doi. 10.1111/bju.13705
- By:
- Publication type:
- Article
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma.
- Published in:
- Carcinogenesis, 2017, v. 38, n. 11, p. 1129, doi. 10.1093/carcin/bgx083
- By:
- Publication type:
- Article
Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
- Published in:
- Cancer (0008543X), 2017, v. 123, n. 18, p. 3617, doi. 10.1002/cncr.30707
- By:
- Publication type:
- Article
Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
- Published in:
- Histopathology, 2017, v. 70, n. 7, p. 1089, doi. 10.1111/his.13167
- By:
- Publication type:
- Article
Non-Clear Cell Renal Cell Carcinomas: Biological Insights and Therapeutic Challenges and Opportunities.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, n. 5, p. 409
- By:
- Publication type:
- Article
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
- Published in:
- Oncologist, 2017, v. 22, n. 3, p. 286, doi. 10.1634/theoncologist.2016-0078
- By:
- Publication type:
- Article
Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.
- Published in:
- Journal of Radiosurgery & SBRT, 2017, v. 5, n. 1, p. 25
- By:
- Publication type:
- Article
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience
- Published in:
- BJU International, 2016, v. 118, n. 2, p. 264, doi. 10.1111/bju.13374
- By:
- Publication type:
- Article
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
- Published in:
- BJU International, 2016, v. 117, n. 5, p. 761, doi. 10.1111/bju.13185
- By:
- Publication type:
- Article
Proteinuria with first-line therapy of metastatic renal cell cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2016, v. 22, n. 2, p. 235, doi. 10.1177/1078155214563153
- By:
- Publication type:
- Article
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Personalised cancer care: promises and challenges of targeted therapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
- Published in:
- Oncologist, 2015, v. 20, n. 10, p. 1140, doi. 10.1634/theoncologist.2015-0143
- By:
- Publication type:
- Article